Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Explora Journeys becomes latest cruise line to be impacted by Middle East war - 2Manual for Vegetarian Protein Powder
- 3James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- 4Instructions to Pick the Ideal Pre-assembled Home for Your Necessities
- 5Where You Could Sleep With Snorlax in Japan, From MIMARU’s Pokémon Rooms to Grand Hyatt Tokyo’s Limited Pokémon Suite
- Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- Instructions to Plan for Your Teeth Substitution Methodology
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- Herzog, German Chancellor Merz discuss final Gaza hostage, Arrow 3 exchange in Jerusalem
- Turning to turkey’s tryptophan to boost mood? Not so fast
- UK clothing inflation climbs as Middle East turmoil threatens wider price rises
- Figure out How to Remain Persuaded During Your Internet based Degree Program
- These four astronauts could soon travel farther from Earth than anyone has gone before
